Latest / Conversations in Lung Cancer Research
Access to Molecular Diagnostics and Treatments Across ANZ: The Past, Present, Future
The identification of molecular subtypes of non-squamous NSCLC continues to grow, spurring the development of targeted therapies designed to target these mutations and prevent the growth of the cancer. People with advanced NSCLC that possess one of these ‘actionable’ mutations and can access targeted treatments can live for many years with very manageable side effects. However, the technology to identify these actionable mutations in a single test and the targeted treatments are not yet accessible to all people with advanced NSCLC.
In this TOGA podcast, we explore access to molecular…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.